Startup profile · funding coverage
Isomorphic Labs funding, valuation and investors
AI-first pharmaceutical research company combining molecular design models, pharma collaborations and an internal therapeutic pipeline.
Verified company research · funding, investors and latest developments
Keep track of Isomorphic Labs
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$2.1B new equity funding · May 12, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$2.1B
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · London, United Kingdom
Investors in latest funding
Lead: Thrive Capital
Other: Alphabet , GV , MGX , Temasek , CapitalG , UK Sovereign AI Fund
Overview
Isomorphic Labs builds AI systems for drug discovery, including the IsoDDE design engine, and works on a portfolio of therapeutic programs. The company announced a $2.1 billion Series B on May 12, 2026 led by Thrive Capital with investors including Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Financing supports drug-design technology, global operations and progress toward clinical programs.
Disclosed funding is not evidence of approved medicines or product revenue. Source: https://www.isomorphiclabs.com/press/isomorphic-labs-funding
Why Isomorphic Labs is interesting
Its May 2026 $2.1B Series B is among the largest disclosed AI-drug-discovery startup rounds; the key question is whether molecular design leads to validated medicines and repeatable partnership economics.
Product & use cases
Molecular modeling and drug design supported by AI, pharma research collaborations and internal drug-development capabilities.
Funding history (newest first)
Series B
2026-05-12 $2.1B new equity funding- Thrive Capital (lead)
- Alphabet (participant)
- GV (participant)
- MGX (participant)
- Temasek (participant)
- CapitalG (participant)
- UK Sovereign AI Fund (participant)
Source: Read source · isomorphiclabs.com
Competitive landscape
Edge: Integrated AI research team and pharmaceutical-development approach with unusually substantial financing.
The company competes across more than one market: with molecular-design vendors for research tools and with drug-owning biotechs for therapeutic assets. Future trials, customer economics and pipeline ownership will be critical tests.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Isomorphic Labs
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.